Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (16328)	10/7/2003 7:31:26 AM
From: Robert K.	Read Replies (3) \| Respond to of 17367

No matter how you cut it many folks wrote off bpi BECAUSE of baxters inaction. Xoma has bpi21 back for about 3 months and has the first (of several planned) pilots underway. Plus xoma has other bpi's for other indications. PLUS xomhas the cash. PLUS xoma soon may have the cash flow. PLUS xoma "may" take on a partner if the deal is right. PLUS a cashed up xoma doesnt have to take ant deal. Plus there is Raptiva and all those "other" LFA-1 indications such as maybe HIV. Plus ther is ING-1. Plus a "maybe" new antibody. Plus all that acquired technology. etc etc etc plus plus plus. skd, imo ,no facts etc.